森萱医药
(920946)
| 流通市值：40.84亿 | | | 总市值：40.86亿 |
| 流通股本：4.27亿 | | | 总股本：4.27亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 460,386,066.76 | 321,194,740.75 | 160,305,237.6 | 552,577,290.5 |
| 营业收入 | 460,386,066.76 | 321,194,740.75 | 160,305,237.6 | 552,577,290.5 |
| 二、营业总成本 | 312,383,616.64 | 211,008,964.37 | 101,738,509.09 | 390,170,490.59 |
| 营业成本 | 236,042,719.88 | 158,292,948.33 | 77,375,997.93 | 295,091,255.67 |
| 税金及附加 | 6,157,153.02 | 4,427,733.25 | 2,387,504.3 | 8,099,490.94 |
| 销售费用 | 11,236,129.78 | 8,085,768.35 | 4,054,457.31 | 14,099,246.73 |
| 管理费用 | 40,392,714.11 | 25,713,236.68 | 12,445,902.23 | 55,159,378.63 |
| 研发费用 | 22,645,769.38 | 14,751,393.11 | 6,013,677.62 | 30,730,314.45 |
| 财务费用 | -4,090,869.53 | -262,115.35 | -539,030.3 | -13,009,195.83 |
| 其中:利息费用 | 491,640.66 | 379,603.6 | 38,562.98 | 94,345.06 |
| 其中:利息收入 | 10,057,094.29 | 4,345,648.4 | 2,195,331.66 | 15,482,191.34 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,856,074.57 | 1,117,186.84 | 530,249.8 | 1,754,904.05 |
| 加:投资收益 | 518,483.02 | 492,376.96 | 273,435.61 | 959,285.82 |
| 资产处置收益 | -65,888.87 | - | - | 2,615.92 |
| 资产减值损失(新) | -1,427,241.45 | -1,486,230.76 | -1,154,203.92 | -8,929,731.82 |
| 信用减值损失(新) | 173,280.09 | -181,857.61 | -473,102.06 | 807,657.59 |
| 其他收益 | 1,220,339.82 | 913,283.99 | 604,093.79 | 2,647,909.07 |
| 四、营业利润 | 150,277,497.3 | 111,040,535.8 | 58,347,201.73 | 159,649,440.54 |
| 加:营业外收入 | 1,416.06 | 1,416 | 1,416 | 1,000.17 |
| 减:营业外支出 | 172,926.09 | 172,926.09 | 5,273.58 | 712,866.56 |
| 五、利润总额 | 150,105,987.27 | 110,869,025.71 | 58,343,344.15 | 158,937,574.15 |
| 减:所得税费用 | 21,006,860.36 | 16,068,768.53 | 8,215,058.35 | 21,166,600.74 |
| 六、净利润 | 129,099,126.91 | 94,800,257.18 | 50,128,285.8 | 137,770,973.41 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 129,099,126.91 | 94,800,257.18 | 50,128,285.8 | 137,770,973.41 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 121,625,502.1 | 90,382,586.58 | 47,046,740.52 | 131,484,558.45 |
| 少数股东损益 | 7,473,624.81 | 4,417,670.6 | 3,081,545.28 | 6,286,414.96 |
| 扣除非经常损益后的净利润 | 119,590,972.41 | 89,105,886.47 | 46,275,797.41 | 127,878,609.91 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.28 | 0.21 | 0.11 | 0.31 |
| (二)稀释每股收益 | 0.28 | 0.21 | 0.11 | 0.31 |
| 九、综合收益总额 | 129,099,126.91 | 94,800,257.18 | 50,128,285.8 | 137,770,973.41 |
| 归属于母公司股东的综合收益总额 | 121,625,502.1 | 90,382,586.58 | 47,046,740.52 | 131,484,558.45 |
| 归属于少数股东的综合收益总额 | 7,473,624.81 | 4,417,670.6 | 3,081,545.28 | 6,286,414.96 |
| 公告日期 | 2026-10-26 | 2026-08-26 | 2026-04-29 | 2026-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |